buformin has been researched along with Cancer of Colon in 2 studies
Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.
buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lea, MA | 1 |
| Kim, H | 1 |
| desBORDES, C | 1 |
| Dil'man, VM | 1 |
| Bershteĭn, LM | 1 |
| Tsyrlina, EV | 1 |
| Bobrov, IuF | 1 |
| Kovaleva, IG | 1 |
2 other studies available for buformin and Cancer of Colon
| Article | Year |
|---|---|
Effects of Biguanides on Growth and Glycolysis of Bladder and Colon Cancer Cells.
Topics: Biguanides; Buformin; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Culture | 2018 |
[Correction of endocrine-metabolic disorders in oncologic patients. The effect of biguanides (phenformin and adebita), miskleron and diphenin].
Topics: Adrenal Cortex Hormones; Aged; Biguanides; Blood Glucose; Body Weight; Breast Neoplasms; Buformin; C | 1975 |